Glenmark Pharmaceuticals Ltd has announced that its U.S. subsidiary, Glenmark Pharmaceuticals Inc., will soon launch Potassium Phosphates Injection USP in the United States market. The product will be available in different vial sizes including 5 mL, 15 mL single-dose vials and a 50 mL pharmacy bulk package vial.
The company said the injection is bioequivalent and therapeutically equivalent to the reference listed drug currently available in the market. This means it provides the same medical benefits and quality as the existing product while offering another treatment option for hospitals and healthcare providers.
According to market data, the Potassium Phosphates Injection market recorded annual sales of around $50.7 million in the 12 months ending January 2026, indicating a stable demand for the product in the U.S. healthcare system.
Marc Kikuchi, President and Business Head for North America at Glenmark Pharmaceuticals, said the launch will help strengthen the company’s institutional product portfolio. He added that Glenmark remains committed to providing high-quality and affordable medicines for patients in need through its growing injectable product pipeline.
Glenmark is a global pharmaceutical company with 11 manufacturing facilities and 6 research and development centers, supplying medicines across 80+ countries worldwide. The company focuses on key therapeutic areas such as respiratory, dermatology, and oncology, while also expanding its generics and specialty drug portfolio.
The upcoming U.S. launch is expected to strengthen Glenmark’s presence in the injectable medicines segment and support its international growth strategy.
Glenmark Pharmaceuticals Ltd (NSE: GLENMARK | BSE: 532296) was trading around ₹2,172.50 on March 16, 2026, slightly higher by 0.08% from the previous close of ₹2,170.70. The company’s market capitalization stands at around ₹61,000 crore.
